Breaking News, Financial News

BioNTech’s 2Q Revenue Soars

Growth due to rapid increases in the supply of BNT162b2 as BioNTech and Pfizer evaluate a third dose to boost efficacy against Delta variant.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech 2Q Revenues: €5.3 billion (revenues were €41.7 million 2Q20) 2Q Earnings: €2.8 billion (loss of €88.3 million 2Q20) Comments: Revenue growth due to rapid increases in the supply of COVID-19 vaccine worldwide. More than one billion doses of BNT162b2 have been supplied to more than 100 countries or territories worldwide as of July 21, 2021. Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution r...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters